The efficacy of intravitreal aflibercept given in a 'treat and extend' regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

The efficacy of intravitreal aflibercept given in a 'treat and extend' regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary)
Indications Retinal oedema
Focus Proof of concept; Therapeutic Use
Sponsors Bayer HealthCare

Most Recent Events

19 Nov 2019 Status changed from active, no longer recruiting to completed.
08 Nov 2017 Planned End Date changed from 2 May 2016 to 2 Feb 2019.
08 Nov 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com